STALICLA’s In-licensing of SFX-01

Goodwin Procter advised STALICLA on the deal. STALICLA announced its worldwide in-licensing of SFX-01, a patented composition of synthetic sulforaphane and alpha-cyclodextrin, from Evgen Pharma in neurodevelopmental...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Insempra’s Investment into Solena Materials

Goodwin Procter advised Insempra on the deal. Insempra announced its strategic investment into Solena Materials Ltd (“Solena”) a synthetic biology company.  Solena, a spin-out from Imperial College...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here